Ollin Biosciences, Inc.

United Statesollin.bio

Ollin Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening ophthalmic conditions.

Read more

Headquartered in Austin, Texas, and established in 2023, Ollin focuses on bispecific antibodies that address multifactorial disease biology in areas such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and thyroid eye disease (TED).

The company’s lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody developed in collaboration with Innovent Biologics. It has demonstrated superior anatomic outcomes and numerically greater vision gains versus faricimab (Vabysmo) in a randomized Phase 1b head-to-head study and is advancing to global Phase 3 trials in DME and wAMD in the second half of 2026.

Ollin’s pipeline also includes OLN102, a first-in-class TSHR/IGF-1R bispecific antibody for TED and Graves’ disease, developed with VelaVigo and expected to enter clinical development in 2026.

Privately held and venture-backed by investors including ARCH Venture Partners, TCGX, a16z Bio+Health, RA Capital, and others, Ollin operates as an emerging player in the ophthalmology sector, leveraging partnerships and a specialized team to challenge established treatments in the retina and ocular autoimmune markets.

Also known as Ollin Bio.

Projects Ollin Biosciences is involved in

None yet. When a new project in the record names Ollin Biosciences as owner, partner or investor, it shows here.

Active projects close to Ollin Biosciences

Ollin Biosciences in chemical industry news

16 November 2026
Johnson & Johnson to buy Ollin Biosciences for $2.2bn

The deal would add OLN324, a Phase 3 bispecific antibody candidate for retinal diseases, to its ophthalmology pipeline.